Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to -$19.0 million.

  • Altimmune's Income towards Parent Company rose 1676.95% to -$19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.0 million, marking a year-over-year increase of 1882.44%. This contributed to the annual value of -$95.1 million for FY2024, which is 752.99% down from last year.
  • Altimmune's Income towards Parent Company amounted to -$19.0 million in Q3 2025, which was up 1676.95% from -$22.1 million recorded in Q2 2025.
  • In the past 5 years, Altimmune's Income towards Parent Company ranged from a high of -$14.9 million in Q1 2021 and a low of -$33.5 million during Q3 2021
  • For the 5-year period, Altimmune's Income towards Parent Company averaged around -$22.4 million, with its median value being -$22.1 million (2025).
  • In the last 5 years, Altimmune's Income towards Parent Company crashed by 28253.86% in 2021 and then skyrocketed by 2983.29% in 2022.
  • Over the past 5 years, Altimmune's Income towards Parent Company (Quarter) stood at -$23.9 million in 2021, then rose by 9.33% to -$21.7 million in 2022, then plummeted by 46.08% to -$31.6 million in 2023, then grew by 26.37% to -$23.3 million in 2024, then increased by 18.39% to -$19.0 million in 2025.
  • Its Income towards Parent Company stands at -$19.0 million for Q3 2025, versus -$22.1 million for Q2 2025 and -$19.6 million for Q1 2025.